Skip to main content
SpringerLink
Log in

Mometasone furoate 0.1 % ointment and hydrogel: a guide to their use in corticosteroid-responsive dermatoses

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Mometasone furoate is a potent corticosteroid for dermatological use. Ointment and hydrogel formulations containing 0.1 % (i.e. 1 mg/g) mometasone furoate are effective and well-tolerated options for the topical treatment of corticosteroid-responsive dermatoses. In the treatment of moderate-to severe psoriasis, eczema and atopic dermatitis, the efficacy of mometasone furoate 0.1 % ointment applied once daily was greater than, or similar to, that of several other potent corticosteroids applied twice or three times daily. Mometasone furoate 0.1 % hydrogel, which has been formulated to be more suitable and patient acceptable than lotion formulations, is bioequivalent to mometasone furoate 0.1 % lotion. In the treatment of moderate-to-severe scalp psoriasis, mometasone furoate 0.1 % lotion applied once daily was more effective than other potent corticosteroids applied twice daily. In addition to the advantage of once-daily application, topical mometasone furoate 0.1 % is associated with a low risk of skin atrophy and a very low risk of systemic adverse effects, including the suppression of the hypothalamic-pituitary-adrenal axis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology. Am J Clin Dermatol. 2002;3(1):47–58.

    Article  PubMed  Google Scholar 

  2. Tadicherla S, Ross K, Shenefelt PD, et al. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009;8(12):1093–105.

    PubMed  Google Scholar 

  3. Mori M, Pimpinelli N, Giannotti B. Topical corticosteroids and unwanted local effects: improving the benefit/risk ratio. Drug Saf. 1994;10(5):406–12.

    Article  CAS  PubMed  Google Scholar 

  4. Prakash A, Benfield P. Topical mometasone: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998;55(1):145–63.

    Article  CAS  PubMed  Google Scholar 

  5. Zatamil (mometasone furoate): product information (Australia). Braeside: Ego Pharmaceuticals Pty Ltd.; 2012.

  6. Isogai M, Shimizu H, Esumi Y, et al. Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993;44:141–5.

    Article  CAS  PubMed  Google Scholar 

  7. Blackwell GJ, Carnuccio R, DiRosa M, et al. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature. 1980;287:147–9.

    Article  CAS  PubMed  Google Scholar 

  8. Hammarström S, Hamburg M, Duell EA, et al. Glucocorticoid in inflammatory proliferative skin disease reduces arachidonic acid and hydroxyeicosatetraenoic acids. Science. 1977;197(4307):994–6.

    Article  PubMed  Google Scholar 

  9. Crocker IC, Zhou CY, Bewtra AK, et al. Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol. 1997;78(5):497–505.

    Article  CAS  PubMed  Google Scholar 

  10. Barton BE, Jakway JP, Smith SR, et al. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol. 1991;13(3):251–61.

    Article  CAS  PubMed  Google Scholar 

  11. Michel G, Nowok K, Beetz A, et al. Novel steroid derivative modulates gene express of cytokines and growth regulators. Skin Pharmacol. 1995;8:215–20.

    Article  CAS  PubMed  Google Scholar 

  12. Berti E, Cerri A, Marzano AV, et al. Mometasone furoate decreases adhesion molecule expression in psoriasis. Eur J Dermatol. 1998;8(6):421–6.

    CAS  PubMed  Google Scholar 

  13. Bjerring P. Comparison of the bioactivity of mometasone furoate 0.1 % fatty cream, betamethasone dipropionate 0.05 % cream and betamethasone valerate 0.1 % cream in humans-inhibition of UV-B-induced inflammation monitored by laser doppler blood flowmetry. Skin Pharmacol. 1993;6(3):187–92.

    Article  CAS  PubMed  Google Scholar 

  14. Kecskés A, Heger-Mahn D, Kuhlmann RK, et al. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity. J Am Acad Dermatol. 1993;29:576–80.

    Article  PubMed  Google Scholar 

  15. Abidi A, Ahmad F, Singh SK, et al. Comparison of reservoir effect of topical corticosteroids in an experimental animal model by histamine-induced wheal suppression test. Indian J Pharmacol. 2012;44(6):722–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Higashi N, Katagiri K. Percutaneous absorption of 0.1 % mometasone furoate ointment fate, excretion and adrenocortical suppression [in Japanese]. Skin Res. 1990;32(3):395–402.

    CAS  Google Scholar 

  17. Zatamil (mometasone furoate 0.1 %w/w): consumer medicine information (Australia). Braeside: Ego Pharmaceuticals Pty Ltd.; 2012.

  18. Bressinck R, Williams J, Peets E. Comparison of the effect of mometasone furoate ointment 0.1 %, and hydrocortisone ointment 1 %, on adrenocortical function in psoriasis patients. Todays Ther Trends. 1988;5(4):25–35.

  19. Katz HI, Prawer SE, Watson MJ, et al. Mometasone furoate ointment 0.1 % vs. hydrocortisone ointment 1.0 % in psoriasis: atrophogenic potential. Int J Dermatol. 1989;28:342–4.

    Article  CAS  PubMed  Google Scholar 

  20. Medansky RS, Brody NI, Kanof NB, et al. Clinical investigations of mometasone furoate: a novel nonfluorinated, topical corticosteroid. Semin Dermatol. 1987;6(2):94–100.

    Google Scholar 

  21. Svensson Å, Reidhav I, Gisslén H, et al. A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res. 1992;52:390–6.

    Article  Google Scholar 

  22. De Villez RL. Efficacy and safety of mometasone furoate 0.1 % once daily versus fluticasone propionate 0.005 % twice daily in the management of psoriasis. Adv Ther. 1998;15(2):92–7.

    Google Scholar 

  23. Medansky RS, Bressinck R, Cole GW, et al. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis. 1988;42:480–5.

    CAS  PubMed  Google Scholar 

  24. Rani Z, Kazmi AH, Sheikh RA, et al. Efficacy, safety and tolerability of mometasone furoate 0.1 % ointment in chronic eczema. J Pak Assoc Dermatol. 2007;17(1):21–7.

  25. Katsarou A, Makris M, Papagiannaki K, et al. Tacrolimus 0.1 % vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol. 2012;22(2):192–6.

    CAS  PubMed  Google Scholar 

  26. Marchesi E, Rozzoni M, Pini P, et al. Comparative study of mometasone furoate and betamethasone dipropionate in the treatment of atopic dermatitis. G Ital Dermatol Venereol. 1994;29(1–2):IX–XII.

  27. Peharda V, Gruber F, Prpic L, et al. Comparison of mometasone furoate 0.1 % ointment and betamethasone dipropionate 0.05 % ointment in the treatment of psoriasis vulgaris. Acta Dermatovenerol Croat. 2000;8(4):223–6.

  28. Vanderploeg DE, Cornell RC, Binder R, et al. Clinical trial in scalp psorisis: mometasone furoate 0.1 % applied once daily vs betamethasone valerate lotion 0.1 % applied twice daily. Acta Ther. 1989;15:145–52.

    Google Scholar 

  29. Swinehart JM, Barkoff JR, Dvorkin D, et al. Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis. Int J Dermatol. 1989;28:680–1.

    Article  CAS  PubMed  Google Scholar 

  30. Schnopp C, Holtmann C, Stock S, et al. Topical steroids under wet-wrap dressings in atopic dermatitis: a vehicle-controlled trial. Dermatology. 2002;204(1):56–9.

    Article  CAS  PubMed  Google Scholar 

  31. Janmohamed SR, Oranje AP, Devillers AC, et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2014;70(6):1076–82.

    Article  CAS  PubMed  Google Scholar 

  32. Pei AY, Chan HH, Ho KM. The effectiveness of wet wrap dressings using 0.1 % mometasone furoate and 0.005 % fluticasone proprionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr Dermatol. 2001;18(4):343–8.

    Article  CAS  PubMed  Google Scholar 

  33. Virgili A, Borghi A, Toni G, et al. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br J Dermatol. 2014;171(2):388–96.

    Article  CAS  PubMed  Google Scholar 

  34. Virgili A, Borghi A, Minghetti S, et al. Mometasone furoate 0.1 % ointment in the treatment of vulvar lichen sclerosus: a study of efficacy and safety on a large cohort of patients. J Eur Acad Dermatol Venereol. 2014;28(7):943–8.

    Article  CAS  PubMed  Google Scholar 

  35. Borghi A, Corazza M, Minghetti S, et al. Continuous vs. tapering application of the potent topical corticosteroid mometasone furoate in the treatment of vulvar lichen sclerosus: results of a randomized trial. Br J Dermatol. 2015;173(6):1381–6.

    Article  CAS  PubMed  Google Scholar 

  36. Corazza M, Borghi A, Minghetti S, et al. Clobetasol propionate vs. mometasone furoate in 1-year proactive maintenance therapy of vulvar lichen sclerosus: results from a comparative trial. J Eur Acad Dermatol Venereol. 2016;30(6):956–61.

    Article  CAS  PubMed  Google Scholar 

  37. Virgili A, Minghetti S, Borghi A, et al. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br J Dermatol. 2013;168(6):1316–24.

    Article  CAS  PubMed  Google Scholar 

  38. Virgili A, Corazza M, Minghetti S, et al. Growing evidence for topical mometasone furoate in the treatment of vulvar lichen sclerosus. Maturitas. 2015;80(1):113–5.

    Article  CAS  PubMed  Google Scholar 

  39. Pérez-López FR, Ceausu I, Depypere H, et al. EMAS clinical guide: vulvar lichen sclerosus in peri and postmenopausal women. Maturitas. 2013;74(3):279–82.

    Article  PubMed  Google Scholar 

  40. Greive KA, Barnes TM. Bioequivalence of 0.1 % mometasone furoate lotion to 0.1 % mometasone furoate hydrogel. Australas J Dermatol. 2016;57(2):e39–45.

    Article  PubMed  Google Scholar 

  41. Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comphrehensive review. Drug Saf. 2015;38(5):493–509.

    Article  CAS  PubMed  Google Scholar 

  42. Brasch J. The atrophogenic potential of mometasone furoate in a clinical long-term study [in German]. Z Hautkr. 1991;66(9):785–7.

    Google Scholar 

  43. Kerscher MJ, Hart H, Korting HC, et al. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther. 1995;33:187–9.

    CAS  PubMed  Google Scholar 

  44. Kelly JW, Cains GD, Railings M, et al. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Australas J Dermatol. 1991;32(2):85–91.

    Article  CAS  PubMed  Google Scholar 

  45. Wach F, Bosserhoff A, Kurzidym U, et al. Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro. Skin Pharmacol Appl Skin Physiol. 1998;11(1):43–51.

    Article  CAS  PubMed  Google Scholar 

  46. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency. Am J Clin Dermatol. 2002;3(3):141–7.

    Article  PubMed  Google Scholar 

  47. Dooms-Goossens A, Lepoittevin J-R. Studies on the contact allergenic potential of momethasone furoate: a clinical and molecular study. Eur J Dermatol. 1996;6:339–40.

    CAS  Google Scholar 

  48. Wilkinson SM, Beck MH. Fluticasone propionate and mometasone furoate have a low risk of contact sensitization. Contact Dermat. 1996;34:365–6.

    Article  CAS  Google Scholar 

  49. Räsänen L, Tuomi M-L. Cross-sensitization to mometasone furoate in patients with corticosteroid contact allergy. Contact Dermat. 1992;27:323–5.

    Article  Google Scholar 

  50. Salgado ACGB, da Silva AMNN, Machado MCJC, et al. Development, stability and in vitro permeation studies of gels containing mometasone furoate for the treatment of dermatitis of the scalp. Brazil J Pharm Sci. 2010;46(1):109–14.

    CAS  Google Scholar 

  51. Salgado A, Raposo S, Marto J, et al. Mometasone furoate hydrogel for scalp use: in vitro and in vivo evaluation. Pharm Dev Technol. 2014;19(5):618–22.

    Article  CAS  PubMed  Google Scholar 

  52. Feldman SR, Housman TS. Patient’s vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221–4.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: A. Borghi, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; A.P. Oranje, Department of Dermatology, Maasstad Hospital, Rotterdam, The Netherlands; H. Riberio, Research Institute for Medicines and Pharmaceutical Sciences, University of Lisbon, Lisbon, Portugal. During the peer review process, the manufacturer of Zatamil® was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    K. A. Lyseng-Williamson

Authors
  1. K. A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Mometasone furoate 0.1 % ointment and hydrogel: a guide to their use in corticosteroid-responsive dermatoses. Drugs Ther Perspect 32, 407–413 (2016). https://doi.org/10.1007/s40267-016-0339-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0339-9

Keywords

Search

Navigation